These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 27194729)

  • 1. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice.
    Shono Y; Docampo MD; Peled JU; Perobelli SM; Velardi E; Tsai JJ; Slingerland AE; Smith OM; Young LF; Gupta J; Lieberman SR; Jay HV; Ahr KF; Porosnicu Rodriguez KA; Xu K; Calarfiore M; Poeck H; Caballero S; Devlin SM; Rapaport F; Dudakov JA; Hanash AM; Gyurkocza B; Murphy GF; Gomes C; Liu C; Moss EL; Falconer SB; Bhatt AS; Taur Y; Pamer EG; van den Brink MRM; Jenq RR
    Sci Transl Med; 2016 May; 8(339):339ra71. PubMed ID: 27194729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gut microbiota and graft-versus-host disease: broad-spectrum antibiotic use increases post-allogeneic hematopoietic stem cell transplant graft-versus-host disease-related mortality].
    Shono Y
    Rinsho Ketsueki; 2017; 58(7):835-842. PubMed ID: 28781282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piperacillin-tazobactam vs. imipenem-cilastatin as empirical therapy in hematopoietic stem cell transplantation recipients with febrile neutropenia.
    Jing Y; Li J; Yuan L; Zhao X; Wang Q; Yu L; Zhou D; Huang W
    Clin Transplant; 2016 Mar; 30(3):263-9. PubMed ID: 26701371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
    Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
    Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaerobic Antibiotics and the Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
    Tanaka JS; Young RR; Heston SM; Jenkins K; Spees LP; Sung AD; Corbet K; Thompson JC; Bohannon L; Martin PL; Stokhuyzen A; Vinesett R; Ward DV; Bhattarai SK; Bucci V; Arshad M; Seed PC; Kelly MS
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2053-2060. PubMed ID: 32682948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
    Eklund AE; Nord CE
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():79-85. PubMed ID: 8383657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia.
    Vural S; Erdem E; Gulec SG; Yildirmak Y; Kebudi R
    Pediatr Int; 2010 Apr; 52(2):262-7. PubMed ID: 19744230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection.
    Erasmo AA; Crisostomo AC; Yan LN; Hong YS; Lee KU; Lo CM
    Asian J Surg; 2004 Jul; 27(3):227-35. PubMed ID: 15564167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.
    Jaccard C; Troillet N; Harbarth S; Zanetti G; Aymon D; Schneider R; Chiolero R; Ricou B; Romand J; Huber O; Ambrosetti P; Praz G; Lew D; Bille J; Glauser MP; Cometta A
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2966-72. PubMed ID: 9797234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteration of Gut Microbiota Composition and Diversity in Acute and/or Chronic Graft-versus-Host Disease Following Hematopoietic Stem Cell Transplantation: A Prospective Cohort Study.
    Gavriilaki E; Christoforidi M; Ouranos K; Minti F; Mallouri D; Varelas C; Lazaridou A; Baldoumi E; Panteliadou A; Bousiou Z; Batsis I; Sakellari I; Gioula G
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996)].
    Figuera A ; Rivero N; Pajuelo F; Font P; Leyra F; de La Cámara R; Arranz R; María Fernández Rañada J
    Med Clin (Barc); 2001 May; 116(16):610-1. PubMed ID: 11412645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia.
    Youssif E; Aseeri M; Khoshhal S
    J Infect Public Health; 2018; 11(4):486-490. PubMed ID: 29153444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections.
    Brismar B; Malmborg AS; Tunevall G; Wretlind B; Bergman L; Mentzing LO; Nyström PO; Kihlström E; Bäckstrand B; Skau T
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2766-73. PubMed ID: 1336347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital.
    Saltoglu N; Dalkiran A; Tetiker T; Bayram H; Tasova Y; Dalay C; Sert M
    Clin Microbiol Infect; 2010 Aug; 16(8):1252-7. PubMed ID: 19832720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections.
    Naber KG; Savov O; Salmen HC
    Int J Antimicrob Agents; 2002 Feb; 19(2):95-103. PubMed ID: 11850161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections.
    Niinikoski J; Havia T; Alhava E; Pääkkönen M; Miettinen P; Kivilaakso E; Haapiainen R; Matikainen M; Laitinen S
    Surg Gynecol Obstet; 1993 Mar; 176(3):255-61. PubMed ID: 8382381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection.
    Dietrich ES; Schubert B; Ebner W; Daschner F
    Pharmacoeconomics; 2001 Jan; 19(1):79-94. PubMed ID: 11252548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections.
    Jhee SS; Gill MA; Yellin AE; Berne TV; Heseltine PN; Appleman MD
    Clin Ther; 1995; 17(1):126-35. PubMed ID: 7758055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients.
    Hundeshagen G; Herndon DN; Capek KD; Branski LK; Voigt CD; Killion EA; Cambiaso-Daniel J; Sljivich M; De Crescenzo A; Mlcak RP; Kinsky MP; Finnerty CC; Norbury WB
    Crit Care; 2017 Dec; 21(1):318. PubMed ID: 29262848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of prophylactic treatment with intravenous piperacillin/tazobactam in patients undergoing hematopoietic stem cell transplantation.
    Kroschinsky F; Wichmann G; Bornhauser M; Ordemann R; Schuler U; Ehninger G; Hanel M
    Transpl Infect Dis; 2002 Sep; 4(3):132-6. PubMed ID: 12421457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.